- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650
infliximab is an approved drug (FDA (1998), EMA (1999))
Compound class: Antibody
Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 .
View more information in the IUPHAR Pharmacology Education Project: infliximab
|Infliximab has been reported to induce an anti-chimeric antibody response in almost 15% of Crohn's disease patients (47 tested) . This indicates that as predicited, humans can mount an immune response to whole murine variable domains, and is the underlying rationale promoting the development of clinical antibodies with variable domains with more human character (i.e. humanised or fully human monoclonal developments).|
|Selectivity at ligand targets|
|Key to terms and symbols||Click column headers to sort|